NO320263B1 - Naeringsstoff til behandling av metabolsk syndrom - Google Patents

Naeringsstoff til behandling av metabolsk syndrom Download PDF

Info

Publication number: NO320263B1
Authority: NO; Norway
Prior art keywords: nutrient; weight; fatty acids; acid; accordance
Prior art date: 1996-11-20

Application number

NO19975299A

Other languages

English (en)

Norwegian (no)

Other versions

NO975299L (no

NO975299D0 (no

Inventor

Hans-Ulrich Bernhard Klor

Annette Hauenschild

Original Assignee

Nutricia Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-20

Filing date

1997-11-19

Publication date

2005-11-14

1997-11-19 Application filed by Nutricia Nv filed Critical Nutricia Nv

1997-11-19 Publication of NO975299D0 publication Critical patent/NO975299D0/no

1998-05-22 Publication of NO975299L publication Critical patent/NO975299L/no

2005-11-14 Publication of NO320263B1 publication Critical patent/NO320263B1/no

Links

208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 10
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 10
235000015097 nutrients Nutrition 0.000 title claims description 34
239000003925 fat Substances 0.000 claims abstract description 35
235000019197 fats Nutrition 0.000 claims abstract description 35
235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 24
229930195729 fatty acid Natural products 0.000 claims abstract description 24
239000000194 fatty acid Substances 0.000 claims abstract description 24
150000004665 fatty acids Chemical class 0.000 claims abstract description 23
239000000203 mixture Substances 0.000 claims abstract description 20
235000018102 proteins Nutrition 0.000 claims abstract description 19
102000004169 proteins and genes Human genes 0.000 claims abstract description 19
108090000623 proteins and genes Proteins 0.000 claims abstract description 19
150000001720 carbohydrates Chemical class 0.000 claims abstract description 18
235000014633 carbohydrates Nutrition 0.000 claims abstract description 17
235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 16
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 15
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 15
235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 14
229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 14
150000002632 lipids Chemical class 0.000 claims abstract description 13
150000004667 medium chain fatty acids Chemical class 0.000 claims abstract description 12
235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 11
208000006575 hypertriglyceridemia Diseases 0.000 claims abstract description 7
208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 5
235000016709 nutrition Nutrition 0.000 claims abstract description 5
206010020606 Hyperchylomicronaemia Diseases 0.000 claims abstract description 4
235000013305 food Nutrition 0.000 claims abstract description 3
239000000126 substance Substances 0.000 claims description 10
239000004615 ingredient Substances 0.000 claims description 9
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 7
239000000843 powder Substances 0.000 claims description 6
235000020778 linoleic acid Nutrition 0.000 claims description 5
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 5
235000020665 omega-6 fatty acid Nutrition 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 3
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 3
235000015872 dietary supplement Nutrition 0.000 claims description 3
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 3
201000011110 familial lipoprotein lipase deficiency Diseases 0.000 claims description 3
208000020346 hyperlipoproteinemia Diseases 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 2
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract description 16
229940090949 docosahexaenoic acid Drugs 0.000 abstract description 8
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract description 6
YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 abstract description 4
239000000470 constituent Substances 0.000 abstract description 4
OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 abstract description 3
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 abstract description 3
JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 abstract description 3
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 abstract description 2
IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 abstract description 2
229960002446 octanoic acid Drugs 0.000 abstract description 2
208000011580 syndromic disease Diseases 0.000 abstract description 2
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 abstract 1
235000021294 Docosapentaenoic acid Nutrition 0.000 abstract 1
239000000463 material Substances 0.000 description 8
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 7
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 7
235000021323 fish oil Nutrition 0.000 description 7
125000004432 carbon atom Chemical group C* 0.000 description 6
239000000835 fiber Substances 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 5
235000010445 lecithin Nutrition 0.000 description 5
239000000787 lecithin Substances 0.000 description 5
229960004232 linoleic acid Drugs 0.000 description 5
239000013589 supplement Substances 0.000 description 5
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 4
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
239000005642 Oleic acid Substances 0.000 description 4
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
229940057917 medium chain triglycerides Drugs 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
235000021313 oleic acid Nutrition 0.000 description 4
239000000047 product Substances 0.000 description 4
YUFFSWGQGVEMMI-UHFFFAOYSA-N (7Z,10Z,13Z,16Z,19Z)-7,10,13,16,19-docosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCCC(O)=O YUFFSWGQGVEMMI-UHFFFAOYSA-N 0.000 description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
239000005639 Lauric acid Substances 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
HQPCSDADVLFHHO-LTKCOYKYSA-N all-cis-8,11,14,17-icosatetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HQPCSDADVLFHHO-LTKCOYKYSA-N 0.000 description 3
JIWBIWFOSCKQMA-LTKCOYKYSA-N all-cis-octadeca-6,9,12,15-tetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O JIWBIWFOSCKQMA-LTKCOYKYSA-N 0.000 description 3
235000020661 alpha-linolenic acid Nutrition 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
XIVFQYWMMJWUCD-UHFFFAOYSA-N dihydrophaseic acid Natural products C1C(O)CC2(C)OCC1(C)C2(O)C=CC(C)=CC(O)=O XIVFQYWMMJWUCD-UHFFFAOYSA-N 0.000 description 3
150000002016 disaccharides Chemical class 0.000 description 3
VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
229960004488 linolenic acid Drugs 0.000 description 3
150000004668 long chain fatty acids Chemical class 0.000 description 3
239000011707 mineral Substances 0.000 description 3
235000010755 mineral Nutrition 0.000 description 3
150000002772 monosaccharides Chemical class 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
235000013619 trace mineral Nutrition 0.000 description 3
239000011573 trace mineral Substances 0.000 description 3
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
235000013343 vitamin Nutrition 0.000 description 3
229930003231 vitamin Natural products 0.000 description 3
239000011782 vitamin Substances 0.000 description 3
229940088594 vitamin Drugs 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
-1 C18:4) Chemical compound 0.000 description 2
108010076119 Caseins Proteins 0.000 description 2
102000011632 Caseins Human genes 0.000 description 2
206010022489 Insulin Resistance Diseases 0.000 description 2
229920002774 Maltodextrin Polymers 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
235000020664 gamma-linolenic acid Nutrition 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
239000003346 palm kernel oil Substances 0.000 description 2
235000019865 palm kernel oil Nutrition 0.000 description 2
SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
235000003441 saturated fatty acids Nutrition 0.000 description 2
150000004671 saturated fatty acids Chemical class 0.000 description 2
235000012424 soybean oil Nutrition 0.000 description 2
239000003549 soybean oil Substances 0.000 description 2
230000008733 trauma Effects 0.000 description 2
BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 description 1
HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 1
PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
108010082495 Dietary Plant Proteins Proteins 0.000 description 1
208000004930 Fatty Liver Diseases 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
206010018429 Glucose tolerance impaired Diseases 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
229920002488 Hemicellulose Polymers 0.000 description 1
206010019708 Hepatic steatosis Diseases 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
201000001431 Hyperuricemia Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-M L-ascorbate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CIWBSHSKHKDKBQ-JLAZNSOCSA-M 0.000 description 1
150000000994 L-ascorbates Chemical class 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
239000005913 Maltodextrin Substances 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
235000021319 Palmitoleic acid Nutrition 0.000 description 1
240000004713 Pisum sativum Species 0.000 description 1
235000010582 Pisum sativum Nutrition 0.000 description 1
229920000294 Resistant starch Polymers 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
239000005862 Whey Substances 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
108010033929 calcium caseinate Proteins 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229960004203 carnitine Drugs 0.000 description 1
235000021466 carotenoid Nutrition 0.000 description 1
150000001747 carotenoids Chemical class 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
229940021722 caseins Drugs 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000019621 digestibility Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
229940108623 eicosenoic acid Drugs 0.000 description 1
BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
208000010706 fatty liver disease Diseases 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
235000012041 food component Nutrition 0.000 description 1
239000005417 food ingredient Substances 0.000 description 1
229940068517 fruit extracts Drugs 0.000 description 1
VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
229960002733 gamolenic acid Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229920005610 lignin Polymers 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
235000019136 lipoic acid Nutrition 0.000 description 1
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
229940035034 maltodextrin Drugs 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
235000006180 nutrition needs Nutrition 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
229940012843 omega-3 fatty acid Drugs 0.000 description 1
239000006014 omega-3 oil Substances 0.000 description 1
229940033080 omega-6 fatty acid Drugs 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000000419 plant extract Substances 0.000 description 1
235000021085 polyunsaturated fats Nutrition 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000009325 pulmonary function Effects 0.000 description 1
239000002994 raw material Substances 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
235000021254 resistant starch Nutrition 0.000 description 1
230000008458 response to injury Effects 0.000 description 1
229940092258 rosemary extract Drugs 0.000 description 1
235000020748 rosemary extract Nutrition 0.000 description 1
239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
229940080237 sodium caseinate Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
231100000240 steatosis hepatitis Toxicity 0.000 description 1
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
229960002663 thioctic acid Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
125000002640 tocopherol group Chemical class 0.000 description 1
235000019149 tocopherols Nutrition 0.000 description 1
229930003802 tocotrienol Natural products 0.000 description 1
239000011731 tocotrienol Substances 0.000 description 1
229940068778 tocotrienols Drugs 0.000 description 1
235000019148 tocotrienols Nutrition 0.000 description 1
230000007306 turnover Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Nutrition Science (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pediatric Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Obesity (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

NO19975299A 1996-11-20 1997-11-19 Naeringsstoff til behandling av metabolsk syndrom NO320263B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP96203249A EP0843972B1 (de)	1996-11-20	1996-11-20	Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselssyndroms

Publications (3)

Publication Number	Publication Date
NO975299D0 NO975299D0 (no)	1997-11-19
NO975299L NO975299L (no)	1998-05-22
NO320263B1 true NO320263B1 (no)	2005-11-14

Family

ID=8224602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19975299A NO320263B1 (no)	1996-11-20	1997-11-19	Naeringsstoff til behandling av metabolsk syndrom

Country Status (8)

Country	Link
US (1)	US5886037A (de)
EP (1)	EP0843972B1 (de)
AT (1)	ATE221324T1 (de)
DE (1)	DE69622722T2 (de)
DK (1)	DK0843972T3 (de)
ES (1)	ES2179156T3 (de)
NO (1)	NO320263B1 (de)
PT (1)	PT843972E (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69817745T2 (de) *	1997-12-15	2004-07-01	Loders Croklaan B.V.	Nicht-temperierte laurinarme Fettzusammensetzungen
DE19757414A1 (de) *	1997-12-23	1999-07-01	Nutricia Nv	Fettmischung
WO1999058120A1 (en) *	1998-05-08	1999-11-18	Rolf Berge	USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
DE19936831A1 (de) *	1999-08-05	2001-02-08	Basf Ag	Verringerung von Cholesterinoxiden durch n-3-PUFA und Vitamin E
US6340705B1 (en)	1999-09-10	2002-01-22	Monsanto Technology, Llc	Use of α-linolenic acid metabolites for treatment or prevention of cancer
US20070072927A1 (en) *	1999-09-23	2007-03-29	Vita Joseph A	Nutritional supplement for increased energy and stamina
EP1062873A1 (de) *	1999-12-13	2000-12-27	N.V. Nutricia	Verbessertes Säuglingsnährpräparat, Eiweisshydrolysat zur Verwendung in solchem Säuglingsnährpräparat, und Verfahren zur Herstellung solches Hydrolysates
AUPQ673300A0 (en) *	2000-04-06	2000-05-04	Penford Australia Limited	Starch sub-types and lipid metabolism
US7226916B1 (en) *	2000-05-08	2007-06-05	N.V. Nutricia	Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en)	2000-05-08	2007-04-24	N.V. Nutricia	Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US6838451B1 (en)	2000-08-02	2005-01-04	Pharmanutrients	Methods and compositions for the prevention and treatment of inflammation, osteoarthritis, and other degenerative joint diseases
EP1305017A4 (de) *	2000-08-02	2004-01-14	Pharmanutrients	Verfahren und zusammensetzung zur vorbeugung und behandlung von syndrom x
US6927239B1 (en) *	2000-08-02	2005-08-09	Pharmanutrients	Methods and compositions for the attenuation and/or prevention of stress/catabolic responses
US6667064B2 (en) *	2000-08-30	2003-12-23	Pilot Therapeutics, Inc.	Composition and method for treatment of hypertriglyceridemia
WO2002043659A2 (en) *	2000-11-29	2002-06-06	Smithkline Beecham Corporation	Composition containing statins and calcium for improved cardiovascular health
US6864242B2 (en) *	2001-03-05	2005-03-08	Stephen P. Ernest	Enteral formulation
WO2003033633A1 (en) *	2001-10-18	2003-04-24	Council Of Scientific And Industrial Research	Cholesterol lowering structured lipids with omega 3 pufa
US20040018248A1 (en) *	2001-11-29	2004-01-29	Adrianne Bendich	Composition containing statins and calcium for improved cardiovascular health
US20030166614A1 (en) *	2002-03-01	2003-09-04	Harrison Stanley F.	Method for reducing cholesterol and triglycerides
DE10214005A1 (de) *	2002-03-27	2003-10-09	Volker Bartz	Blutfettsenker zur oralen Einnahme, bestehend aus einem Gemisch aus den Omega-3-Fettsäuren EPA (Eicosapentaensäure) und DHA (Docosapentaensäure) und Pektin und/oder Guar als wirksame Substanzen, sowie gegebenenfalls zusätzlichen Stoffen wie antioxidative Vitamine, Aminosäuren und Spurenelemente
FI114894B (fi) *	2002-05-02	2005-01-31	Omecol Finland Oy	Elintarvikekoostumus
JP2004043337A (ja) *	2002-07-10	2004-02-12	Nisshin Oillio Ltd	血中中性脂肪濃度調整剤
TW200412942A (en) *	2002-08-06	2004-08-01	Abbott Lab	Appetite control method
DE10254584A1 (de) *	2002-11-22	2004-06-09	HORST HEIRLER PROJEKTE für Ernährung, Medizin, Ökologie	Verwendung von mittelkettigen Triglyceriden (MCT) zur ernährungsphysiologischen Optimierung des Fettsäurenspektrums in einem diätetischen Lebensmittel für Diabetiker
CA2515368A1 (en) *	2003-02-13	2004-08-26	Luciano Rossetti	Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
US7323206B1 (en)	2003-03-04	2008-01-29	B. Braun Medical Inc.	Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
US20050266051A1 (en) *	2004-05-27	2005-12-01	The Procter & Gamble Company	Pet food compositions and methods
EP1776017A2 (de) *	2004-07-13	2007-04-25	Rutgers, The State University Of New Jersey	Mit omega-fettsäure angereicherte nahrungsmittelprodukte und verfahren zu ihrer herstellung
AU2005264781B2 (en) *	2004-07-19	2011-07-28	Life Science Nutrition As	Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities
US7456270B2 (en)	2004-09-01	2008-11-25	Abbott Laboratories	Δ6-desaturase genes and uses thereof
WO2006041922A2 (en) *	2004-10-08	2006-04-20	Dara Biosciences, Inc.	Agents and methods for administration to the central nervous system
EP1656839A1 (de) *	2004-11-11	2006-05-17	N.V. Nutricia	Nahrung, die eine Lipidmischung enthält
CN101242748A (zh) *	2004-11-26	2008-08-13	荷兰纽迪希亚公司	含有蛋白酶抑制剂的婴儿营养品
US8431165B2 (en) *	2004-12-13	2013-04-30	Swing Aerobics Licensing, Inc.	Medicament for treatment of cancer and other diseases
US8092839B2 (en) *	2004-12-13	2012-01-10	Swing Aerobics Licensing, Inc.	Medicament for treatment of cancer and other diseases
WO2006088798A2 (en) *	2005-02-14	2006-08-24	Albert Einstein College Of Medicine Of Yeshiva University	Modulation of hypothalamic atp-sensitive potassium channels
CA2537452C (en) *	2005-03-09	2013-12-24	Abbott Laboratories	Concentrated human milk fortifier liquid
EP2241195A1 (de)	2005-04-06	2010-10-20	Nestec S.A.	Methode und Zubereitung zur Verbesserung der Kontrolle des Glukosespiegels und der Wirksammkeit Insulins durch Ernährung
US20070031538A1 (en) *	2005-07-13	2007-02-08	Gul Konuklar	Liquid nutritional compositions containing n-3 polyunsaturated fatty acids
US9179702B2 (en) *	2005-07-13	2015-11-10	Abbott Laboratories	Liquid nutritional compositions containing unsaturated fatty acids
WO2007063143A1 (es) *	2005-11-30	2007-06-07	Katry Inversiones, S.L.	Mezcla de lipidos y su utilización para preparar un producto destinado a la adminitracion enteral u oral
US20070218183A1 (en) *	2006-03-14	2007-09-20	Bunge Oils, Inc.	Oil composition of conjugated linoleic acid
US20080089981A1 (en) *	2006-10-17	2008-04-17	N.V. Nutricia	Ketogenic diet
GB2444896B (en) *	2006-12-18	2010-05-19	Nutraceuticals Ltd	Compositions comprising polyunsaturated fatty acids
US8343541B2 (en) *	2007-03-15	2013-01-01	Soft Gel Technologies, Inc.	Ubiquinol and alpha lipoic acid compositions
WO2009002148A1 (en) *	2007-06-27	2008-12-31	N.V. Nutricia	Food composition for prodromal dementia patients
ES2808406T3 (es)	2007-06-26	2021-02-26	Nutricia Nv	Mejora de la memoria en sujetos con un mini examen del estado mental de 24-26
WO2009002146A1 (en)	2007-06-26	2008-12-31	N.V. Nutricia	Supporting activities of daily living
WO2009002145A1 (en) *	2007-06-26	2008-12-31	N.V. Nutricia	Lipid composition for improving function of brain functioning
US7943163B2 (en) *	2007-08-22	2011-05-17	Response Scientific, Inc.	Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
US20090054513A1 (en) *	2007-08-22	2009-02-26	Response Scientific, Inc.	Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
EP2609812B1 (de)	2007-12-20	2018-08-29	N.V. Nutricia	Flüssige Produkte mit Nukleotiden/Nukleosiden
WO2009099886A1 (en) *	2008-01-31	2009-08-13	Monsanto Technology Llc	Methods of improving dha deposition and related function and/or development
ES2558609T3 (es) *	2008-02-01	2016-02-05	Blackberry Limited	Sistema y método para sincronización de temporización de enlace ascendente en combinación con recepción discontinua
DK2334295T3 (en)	2008-09-02	2017-10-09	Amarin Pharmaceuticals Ie Ltd	PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
WO2010049142A1 (de) *	2008-10-29	2010-05-06	Lipid4Life Gmbh	Ernährungszusammensetzung enthaltend omega- 3 -fettsäuren und mct
JP5059947B2 (ja)	2008-11-06	2012-10-31	日清オイリオグループ株式会社	濃厚流動食
US8060617B2 (en) *	2008-12-19	2011-11-15	Cisco Technology, Inc.	Reserving network resources during scheduling of meeting event
US9034389B2 (en)	2009-03-11	2015-05-19	Stable Solutions Llc	Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en)	2009-03-11	2015-03-31	Stable Solutions Llc	Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
AU2016219657B2 (en) *	2009-04-29	2018-02-01	Amarin Pharmaceuticals Ireland Limited	Stable pharmaceutical composition and methods of using same
AU2010241567B2 (en)	2009-04-29	2013-10-31	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
WO2010127103A1 (en) *	2009-04-29	2010-11-04	Amarin Pharma, Inc.	Stable pharmaceutical composition and methods of using same
US8455472B2 (en)	2009-06-15	2013-06-04	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
KR101798670B1 (ko)	2009-09-23	2017-11-16	아마린 코포레이션 피엘씨	오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법
US8372465B2 (en)	2010-02-17	2013-02-12	Bunge Oils, Inc.	Oil compositions of stearidonic acid
CN103260419B (zh)	2010-11-02	2014-12-24	雅培制药有限公司	稳定的浓缩液体母乳强化剂
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ727980A (en)	2010-11-29	2018-08-31	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US20130131170A1 (en)	2011-11-07	2013-05-23	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
EP3348262A1 (de) *	2012-01-06	2018-07-18	Omthera Pharmaceuticals Inc.	Verfahren zur herstellung von dpa-angereicherten zusammensetzungen von mehrfach ungesättigten omega-3-fettsäuren in freier säureform
EP2800469B1 (de)	2012-01-06	2021-08-25	Amarin Pharmaceuticals Ireland Limited	Zusammensetzungen und verfahren zur senkung der konzentration an hochsensitivem c-reaktiven protein (hs-crp) bei einer person
JP6173437B2 (ja)	2012-05-07	2017-08-02	オムセラ・ファーマシューティカルズ・インコーポレイテッド	スタチン及びω−３脂肪酸の組成物
WO2013192109A1 (en)	2012-06-17	2013-12-27	Matinas Biopharma, Inc.	Omega-3 pentaenoic acid compositions and methods of use
RS61557B1 (sr)	2012-06-29	2021-04-29	Amarin Pharmaceuticals Ie Ltd	Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline
WO2014027015A1 (en) *	2012-08-14	2014-02-20	Nestec S.A.	Low ph process for the preparation of pasteurized compositions comprising high levels of fat, protein and carbohydrate
WO2014027022A1 (en) *	2012-08-14	2014-02-20	Nestec S.A.	Dietetic compositions for the treatment of malnutrition, neurological diseases and metabolic diseases
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015127320A2 (en) *	2014-02-20	2015-08-27	Iycus, Llc	Single serve beverage compositions
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2017167418A1 (en) *	2016-03-30	2017-10-05	Nestec S.A.	Nutritional compositions and their use
WO2018102914A1 (en) *	2016-12-06	2018-06-14	Transfert Plus, Société En Commandite	Use of medium-chain triglycerides for the management of metabolic conditions
US10966951B2 (en)	2017-05-19	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2020068163A1 (en)	2018-09-24	2020-04-02	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of cardiovascular events in a subject
JP2020150805A (ja) *	2019-03-18	2020-09-24	株式会社０	タンパク質高含有アイスクリーム
KR20240012390A (ko)	2021-04-21	2024-01-29	애머린 파마슈티칼스 아일랜드 리미티드	심부전의 위험을 감소시키는 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS59172416A (ja) *	1983-03-18	1984-09-29	Terumo Corp	脂肪輸液
US4752618A (en) *	1984-07-12	1988-06-21	New England Deaconess Hospital	Method of minimizing efects of infection through diet
US4871768A (en) *	1984-07-12	1989-10-03	New England Deaconess Hospital Corporation	Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US4678808A (en) *	1985-10-15	1987-07-07	Baxter Travenol Laboratories, Inc.	Rapid acting intravenous emulsions of omega-3 fatty acid esters
DE3721137A1 (de) *	1987-06-26	1989-01-05	Dietl Hans	Fettemulsion zur intravenoesen anwendung
DE3734147C2 (de) *	1987-10-09	1998-10-29	Braun Melsungen Ag	Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
US5288512A (en) *	1987-12-15	1994-02-22	The Procter & Gamble Company	Reduced calorie fats made from triglycerides containing medium and long chain fatty acids
US5000975A (en) *	1988-12-29	1991-03-19	American Home Products Corporation	Randomized palm oil fat composition for infant formulas
ES2033193B1 (es) *	1990-10-30	1994-01-16	Ganadera Union Ind Agro	Mezcla grasa para nutricion infantil y de adultos.
US5223285A (en)	1992-03-31	1993-06-29	Abbott Laboratories	Nutritional product for pulmonary patients
DE4304394A1 (en)	1993-02-13	1993-09-02	Fresenius Ag	Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
US5444054A (en) *	1994-04-01	1995-08-22	Abbott Labatories	Method of treating ulcerative colitis
US5574065A (en)	1994-04-21	1996-11-12	Clintec Nutrition Co.	Method and composition for normalizing injury response
DE4417851C1 (de)	1994-05-20	1995-10-05	Horst Heirler	Diätetisches Lebensmittel mit mittelkettigen Fettsäuren und dessen Verwendung
DE19503993A1 (de)	1995-02-08	1996-08-14	Johann Friedrich Dr Med Desaga	Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen

1996
- 1996-11-20 DK DK96203249T patent/DK0843972T3/da active
- 1996-11-20 AT AT96203249T patent/ATE221324T1/de active
- 1996-11-20 EP EP96203249A patent/EP0843972B1/de not_active Expired - Lifetime
- 1996-11-20 ES ES96203249T patent/ES2179156T3/es not_active Expired - Lifetime
- 1996-11-20 PT PT96203249T patent/PT843972E/pt unknown
- 1996-11-20 DE DE69622722T patent/DE69622722T2/de not_active Expired - Lifetime
1997
- 1997-11-19 NO NO19975299A patent/NO320263B1/no not_active IP Right Cessation
- 1997-11-20 US US08/975,074 patent/US5886037A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0843972A1 (de)	1998-05-27
ES2179156T3 (es)	2003-01-16
ATE221324T1 (de)	2002-08-15
DK0843972T3 (da)	2002-12-02
NO975299L (no)	1998-05-22
DE69622722T2 (de)	2003-02-27
NO975299D0 (no)	1997-11-19
US5886037A (en)	1999-03-23
PT843972E (pt)	2002-12-31
EP0843972B1 (de)	2002-07-31
DE69622722D1 (de)	2002-09-05

Legal Events

Date	Code	Title	Description
2017-12-11	MK1K	Patent expired

Publication	Publication Date	Title
NO320263B1 (no)	2005-11-14	Naeringsstoff til behandling av metabolsk syndrom
Melo et al.	2019	Chia seeds: An ancient grain trending in modern human diets
ES2478869T3 (es)	2014-07-23	Composición nutricional enteral líquida adecuada para alimentación por sonda
Vidgren et al.	1997	Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
Mansbridge et al.	1997	Nutritional factors affecting the fatty acid composition of bovine milk
Hirai et al.	1989	Eicosapentaenoic acid and adult diseases in Japan: epidemiological and clinical aspects
Hulan et al.	1989	Omega-3 fatty acid levels and general performance of commercial broilers fed practical levels of redfish meal
JP5860704B2 (ja)	2016-02-16	水中オメガ−３強化された魚油型非経口栄養エマルション
JPH044298B2 (de)	1992-01-27
IL173967A (en)	2012-04-30	Lipid system comprising omega 3,6,9 fatty acids and its use for the manufacture of a medicament
EP1959746B1 (de)	2009-08-12	Verbesserte fettzusammensetzung
US20090099261A1 (en)	2009-04-16	Omega-3 mixtures
EP2509431B1 (de)	2014-02-26	Ausgewogene fettzusammensetzung und ihre verwendung in einer flüssigen nährstoffzusammensetzung für enterale ernährung
CA2056957A1 (en)	1992-06-08	Nutrition
JPS63297342A (ja)	1988-12-05	合成油脂ならびにこれを含有する脂肪乳剤輸液および経腸栄養剤
Borghi et al.	2006	Omega-3 polyunsaturated fatty acids: Their potential role in blood pressure prevention and management
Broadhurst et al.	2000	Evening primrose oil: pharmacological and clinical applications
Planas et al.	1999	Fatty acid composition of platelet membrane lipids after administration of two different fat emulsions in critically ill patients
Mu	2008	Bioavailability of omega-3 long-chain polyunsaturated fatty acids from foods
Polidori et al.	2013	Oleic acid in milk of different mammalian species
BAgrSc et al.	1995	Diet, hyperlipidaemia and cardiovascular disease
Lyashenko et al.	2023	Screening of lesser known dry-salted fish species for fatty acids, tocopherols, and squalene
Talahalli et al.	2014	Polyunsaturated fatty acids as nutraceuticals
Hulan	1991	Incorporating omega-3 fatty acid into chicken product lipids
Sarıca	2017	Nutrition for Functionality of Poultry Meat and Egg